



Ref: FOIA Reference 2023/24-442

Date: 27th October 2023

Email foi@uhnm.nhs.uk

Dear

I am writing to acknowledge receipt of your email dated 9th October 2023 requesting information under the Freedom of Information Act (2000) regarding Migraine

As of 1st November 2014 University Hospitals of North Midlands NHS Trust (UHNM) manages two hospital sites – Royal Stoke University Hospital, and County Hospital (Stafford). Therefore the response below is for the two sites combined from that date where appropriate.

Q1 We are seeking to understand the funding and delivery of Botox and anti-CGRP monoclonal antibody treatments (Ajoovy, Aimovig, Emgality, Vyepti, Vyduura & Aquipta) for migraine. Could you please answer the following:

Does the Trust commission/fund Botox treatment for migraine (Y/N)?

A1 Yes

Q2 Does the Trust commission/fund anti-CGRP treatments for migraine (Y/N)?

A2 Yes

Q3 Does the Trust actively provide Botox/anti-CGRP treatments for migraine as opposed to sending patients to another trust (Y/N)? In case the Trust does not provide these treatments, please provide the name of the trust to which you refer migraine patients for these treatments?

A3 Yes

Q4 In case the Trust actively provides Botox/anti-CGRP treatments for migraine but does not commission/fund them, then please provide the name(s) of the other NHS organisations that commission/fund these treatments at your trust.

A4 Not applicable

Q5 How many patients have been treated with the following drugs in the past 4 months:

- Atogepant (Aquipta) – any disease

- Erenumab (Aimovig) - any disease
- Eptinezumab (Vypti) – any disease
- Fremanezumab (Ajovy) - any disease
- Galcanezumab (Emgality) - any disease
- Rimegepant (Vydura) – any disease
- Botulinum Toxin (i.e., Botox, Dysport, Xeomin) - migraine ONLY

A5 See below:

- Atogepant (Aquipta) – any disease - 0
- Erenumab (Aimovig) - any disease - 111
- Eptinezumab (Vypti) – any disease - 0
- Fremanezumab (Ajovy) - any disease - 222
- Galcanezumab (Emgality) - any disease - 0
- Rimegepant (Vydura) – any disease - 0
- Botulinum Toxin (i.e., Botox, Dysport, Xeomin) - migraine ONLY - 174

Q6 How many patients have you treated in the last 4 months for chronic migraine (15+ headache days per month) and episodic migraine (4-15 headache days per month) with the following drugs:

Drugs	Chronic Migraine (15+ headache days per month)	Episodic Migraine (4-15 headache days per month)
Atogepant		
Erenumab		
Eptinezumab		
Fremanezumab		
Galcanezumab		
Rimegepant		
Botulinum Toxin		

A6 See below:

Drugs	Chronic Migraine (15+ headache days per month)	Episodic Migraine (4-15 headache days per month)
Atogepant	0	0
Erenumab	105	6
Eptinezumab	0	0
Fremanezumab	217	5
Galcanezumab	0	0
Rimegepant	0	0
Botulinum Toxin	174	0

*Please note that any individuals identified do not give consent for their personal data to be processed for the purposes of direct marketing.

UHNM NHS Trust is a public sector body and governed by EU law. FOI requestors should note that any new Trust requirements over the EU threshold will be subject to these regulations and will be advertised for open competition accordingly.

Where the Trust owns the copyright in information provided, you may re-use the information in line with the conditions set out in the Open Government Licence v3 which is available at <http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/>. Where information was created by third parties, you should contact them directly for permission to re-use the information.

An anonymised copy of this request can be found on the Trust's disclosure log, please note that all requests can be found at the following link: <http://www.uhnm.nhs.uk/aboutus/Statutory-Policies-and-Procedures/Pages/Freedom-of-Information-Disclosure-Log.aspx>

This letter confirms the completion of this request. A log of this request and a copy of this letter will be held by the Trust.

If you have any queries related to the response provided please in the first instance contact my office.

Should you have a complaint about the response or the handling of your request, please also contact my office to request a review of this. If having exhausted the Trust's FOIA complaints process you are still not satisfied, you are entitled to approach the Information Commissioner's Office (ICO) and request an assessment of the manner in which the Trust has managed your request.

The Information Commissioner may be contacted at:

Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF or via www.ico.org.uk.

Yours,



Rachel Montinaro
Data Security and Protection Manager - Records